01
The Boten project
Facility development, initial production modules and the sequence of work needed before routine manufacture.
ManufacturingPharmaceutical manufacturing · Boten, Lao PDR
Building the foundations for pharmaceutical manufacturing in Laos.
A development-stage manufacturing project with a documented initial production scope and a separate, broader generic product portfolio.
Development-stage project Source basis: Boten Biopharmaceutical Manufacturing Project, 15 June 2026. Planning document; not evidence of current operating capacity.
Manufacturing programmeBoten
A project taking shape.
Construction and fit-out · in progress.
The next stage is equipment installation and qualification.
Target Q1 2027 · indicative · Status reviewed · Read the project roadmap
It does not depict Luang Pharma's project, products or installed equipment.
- Project stage
- Construction and fit-outIn progress
- Next project step
- Equipment installation and qualificationTarget Q1 2027 · indicative
- Status reviewed
- Project update
- Commercial supply
- NoneNo Luang Pharma product is on the market.
01 · Programme architecture
Three workstreams with distinct responsibilities.
A building, a portfolio record and a market opportunity each require different evidence.
02
The public portfolio
Generic records for development discussion, with proposed presentations and product-specific evidence boundaries.
Portfolio records
03
Future market access
Product- and destination-specific assessment of regulatory roles, responsibilities and potential partnerships.
PartneringIt does not depict Luang Pharma's project, products or installed equipment.
02 · Documented initial scope
A defined first manufacturing scope.
The June 2026 project brief describes two planned modules. Their engineering scope is presented as a development programme, not as commissioned or licensed capacity.
Module 01Planned
Formulation & filling
Five presentation families are identified in the source plan: lyophilised vials, dual-chamber cartridges, single-chamber lyophilised cartridges, 10 mL oil-based vial injections and 1 mL ampoules.
Review planned modulesModule 02Planned
Protein raw-material production & purification
A separate planned module for protein raw-material production and purification. The website does not present this plan as validated output or a granted manufacturing scope.
Review the module distinctionCataloguePlanned
A broader capability catalogue
The proposed services catalogue extends beyond these initial modules. Every service is marked Planned; inclusion does not establish an installed line or availability.
Explore the catalogueOne facility programme. A wider portfolio roadmap.
The public portfolio contains dosage forms and product types beyond the initial facility modules. A portfolio entry therefore does not establish that a corresponding line is installed, qualified or authorised at Boten.
- Initial Boten project scope
- Two planned production modules documented in the June 2026 project brief.
- Public product portfolio
- Generic development records used for professional discussion; manufacturing route and market status remain product-specific.
03 · Development path
Progress has a sequence.
The project roadmap makes each future milestone visible without treating a target as an achieved stage.
- 01Completed
Facility design
Facility design is recorded as complete. No completion date is supplied.
- 02In progressTarget Q4 2026 · indicative
Construction and fit-out
Construction is in its final stage; completion is an indicative target.
- 03PlannedTarget Q1 2027 · indicative
Equipment installation and qualification
Installed systems would require documented qualification.
- 04PlannedTarget Q2 2027 · indicative
Process and system validation
Process and system evidence would need to be established.
- 05PlannedTarget Q3 2027 · indicative
Manufacturing licence application
Submitting an application does not establish permission to manufacture.
- 06PlannedTarget Q4 2027 · indicative
Regulatory inspection
Inspection is a separate stage from any resulting authorisation.
- 07PlannedTarget Q1 2028 · indicative
First commercial batch
Dependent on applicable permissions and demonstrated readiness.
Project roadmap reviewed . These are indicative project targets, subject to progress and applicable permissions. They are not service launch dates or commitments to supply. A milestone is marked completed only when the company confirms it.
Read the project roadmap04 · Quality before operation
Separate the project plan from the evidence to operate.
Construction, qualification, quality systems, facility permissions, product authorisation and batch release answer different questions. The site keeps those layers distinct.
- 01 · Definition
Product & process
Identify the exact presentation, process and proposed use of the evidence.
- 02 · Preparation
Systems & records
Develop the relevant documentation, training and qualification framework.
- 03 · Evaluation
Review & validation
Connect results to their system, product and accepted criteria.
- 04 · Decision
Applicable permissions
Keep manufacturing authorisation and product registration distinct.
05 · Public portfolio
Depth at the level of the record.
Every count on this page is computed from the public catalogue.
178 public development records, organised by generic identity and presentation.
The catalogue contains 168 medicine records and 10 device or diagnostic records. These are records for professional discussion. They do not establish approval, a manufacturing route or availability.
Representative record · LP-002
Paracetamol Tablets
Proposed strengths, pack options and unresolved release characteristics, kept in separate evidence fields.
06 · Public evidence
Source-led, dated and deliberately limited.
Public project statements are tied to the supplied planning record and documentary imagery. The website does not infer operating readiness, an inspection result or regulatory approval from a photograph.
- Planning source
- Boten Biopharmaceutical Manufacturing ProjectSource date: 15 June 2026
- Website interpretation
- Development plan, not current capability evidence
- Project-stage update
- Reviewed Construction and fit-out · in progress
- Current supply status
- No Luang Pharma product is on the market.Portfolio information is not an offer of supply.
07 · Professional reading
Read the evidence behind a product or supply question.
Guide
Reading a medicine profile
How generic identity, dosage form, proposed strength and controlled labelling fit together.
Read the guideGuide
GMP and product approval
Why facility standards, product authorisation and batch release remain separate evidence layers.
Read the guideGuide
Registration and cross-border supply
Why destination, importer role, product status and permitted supply route must be assessed case by case.
Read the guideProfessional enquiries
Discuss a defined project or product question.
Include your organisation, country or destination, and the specific manufacturing, regulatory or portfolio subject you want to assess.